GET DAILY SIGNALSCuris (CRIS) Q3 2026 Earnings Preview: Narrowing Losses and Pipeline Focus
Key Takeaways
- Curis, Inc. (CRIS) will release its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m. ET, with a conference call set for 4:30 p.m. ET.
- Wall Street consensus calls for a net loss of $2.29 per share on revenue of about $1.00 million.
- A year ago, Curis recorded a loss of $9.80 per share on revenue of $3.18 million, pointing to a significantly narrower expected loss and a projected drop in revenue.
- In the most recent quarter, Curis posted a loss of $4.02 per share, surpassing the $6.95 consensus by $2.93 and continuing a pattern of beating EPS estimates in four of the past eight quarters.
- Attention is expected to center more on clinical updates for emavusertib than on the headline financial figures.
- For more background on CRIS, check its dedicated pages covering major news, recent price action, price targets, and forecasts.
Understanding the Context for Curis’s Report
Curis operates as a clinical-stage biotechnology company centered on emavusertib, an oral small-molecule inhibitor aimed at IRAK4 and FLT3 proteins linked to certain blood cancers. With limited revenue generation, its quarterly updates tend to draw focus on cash reserves, spending control, and clinical trial progress instead of sales growth. The stock has shown notable volatility and fits the profile of a high-risk development-stage name. In this setting, the third quarter release should offer insight into whether the company is advancing its pipeline while maintaining enough financial runway for upcoming data readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Projecting
Analysts anticipate a net loss of $2.29 per share for the third quarter of 2026, paired with revenue near $1.00 million. These estimates stand against a $9.80 per share loss and $3.18 million in revenue from the same quarter last year, highlighting both a substantial improvement in the expected per-share loss and a clear decline in revenue. During the previous quarter, Curis delivered a $4.02 per share loss that beat the $6.95 consensus by $2.93, and it has topped EPS forecasts in four of its last eight reports. Given the early-stage nature of the business, investors will likely track research and development spending along with general and administrative costs as well.
Market Sentiment Heading Into the Release
Sentiment around Curis appears measured as the report approaches. The stock has faced sharp declines over the past year amid high volatility and a relatively small float that can magnify moves after earnings. Investors will probably view the results through the lens of clinical execution and cash runway rather than earnings per share in isolation. Key risks include reliance on financing arrangements, the uncertainties of clinical trials, and competition in oncology. A narrower-than-expected loss or encouraging updates on emavusertib timelines could help sentiment, whereas signs of a tighter cash position or trial delays could pressure the shares.
Forward Outlook and Items to Watch
Outside the headline numbers, management commentary on emavusertib development across multiple studies will be important. Updates on the TakeAim Lymphoma program and the TakeAim CLL combination study are likely to feature prominently on the call. Curis has noted that initial data from the CLL study may arrive before the end of 2026, so the timing and quality of these results represent near-term catalysts. Cash management will stay in focus as well. As a clinical-stage company with modest revenue, Curis depends on financing to support operations, and spending rates will shape the length of its runway. Clarity on the cash position and any expected proceeds from warrant exercises or other financing steps will be useful. Broader conditions in oncology drug development, including rival data and regulatory shifts, could also shape how the market interprets progress. While one quarter is unlikely to alter the long-term path, this update serves as a useful checkpoint on execution, timelines, and financial strength.
Exploring AI Tools for Biotech Analysis
In my own research process, I have found Tickeron’s AI tools helpful for screening opportunities in sectors like biotechnology. The platform allows filtering based on technical patterns, fundamentals, and AI signals, which can surface ideas more efficiently when monitoring names like CRIS alongside wider market trends. For those interested in similar data-driven approaches, the AI Screener offers a practical way to organize scans across thousands of stocks and ETFs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRIS in upward trend: price rose above 50-day moving average on November 04, 2026
CRIS moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CRIS as a result. In 53 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +67.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 42 cases where CRIS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRIS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.439) is normal, around the industry mean (2.904). P/E Ratio (0.233) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a drug company
Industry Biotechnology
Advertisement